SK pharmteco Capacity Update April 2025: Cell & Gene Therapy

SK pharmteco is a CDMO offering services for Small Molecule, Cell and Gene Therapy, and Analytical Testing.

In this presentation, Patrick Lansky, Executive Director of Business Development, will:

• Highlight SK pharmteco's extensive capabilities in supporting the development and manufacturing of cell and gene therapies.
• Delve into our expertise in plasmid science and manufacturing, emphasizing our ability to produce high-quality DNA templates essential for gene therapies and viral vector production.
• Describe our plasmid science capabilities and their impact on derisking viral vector manufacturing.
• Explore our advanced vector manufacturing capabilities, including Adeno-Associated Virus (AAV) and lentiviral platforms.
• Discuss our comprehensive cell therapy manufacturing solutions for both autologous and allogeneic therapies.
• Provide insight into our robust analytical and regulatory support, detailing our approach to product characterization, compliance, and regulatory strategy. 

Join us to learn how SK pharmteco’s integrated capabilities can support the development and manufacturing of your advanced therapies.